KPIs & Operating Metrics(New)
Balance Sheet
Accounts PayablesAccumulated ExpensesAssetsCash & Current InvestmentsCash & EquivalentsCommon EquityCurrent AssetsGoodwillGoodwill & IntangiblesLiabilities and Shareholders EquityLong-Term InvestmentsMinority InterestNon-Current AssetsNon-Current DebtOther Accumulated ExpensesOther Non-Current AssetsOther Non-Current LiabilitiesPayablesPrepaid AssetsRetained EarningsShareholder's EquityShort term DebtShort-term InvestmentsTotal Current LiabilitiesTotal DebtTotal LiabilitiesTotal Non-Current LiabilitiesTreasury Shares
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Others
Ratios

Royalty Pharma (RPRX) Cash & Equivalents (2019 - 2025)

Historic Cash & Equivalents for Royalty Pharma (RPRX) over the last 7 years, with Q3 2025 value amounting to $938.9 million.

  • Royalty Pharma's Cash & Equivalents fell 116.92% to $938.9 million in Q3 2025 from the same period last year, while for Sep 2025 it was $938.9 million, marking a year-over-year decrease of 116.92%. This contributed to the annual value of $929.0 million for FY2024, which is 9476.03% up from last year.
  • Per Royalty Pharma's latest filing, its Cash & Equivalents stood at $938.9 million for Q3 2025, which was down 116.92% from $631.9 million recorded in Q2 2025.
  • In the past 5 years, Royalty Pharma's Cash & Equivalents ranged from a high of $2.2 billion in Q2 2023 and a low of $477.0 million during Q4 2023
  • For the 5-year period, Royalty Pharma's Cash & Equivalents averaged around $1.3 billion, with its median value being $1.1 billion (2025).
  • Its Cash & Equivalents has fluctuated over the past 5 years, first skyrocketed by 89820.95% in 2021, then crashed by 7211.69% in 2023.
  • Quarter analysis of 5 years shows Royalty Pharma's Cash & Equivalents stood at $1.5 billion in 2021, then increased by 11.01% to $1.7 billion in 2022, then crashed by 72.12% to $477.0 million in 2023, then skyrocketed by 94.76% to $929.0 million in 2024, then increased by 1.07% to $938.9 million in 2025.
  • Its last three reported values are $938.9 million in Q3 2025, $631.9 million for Q2 2025, and $1.1 billion during Q1 2025.